AVALO THERAPEUTICS, INC. Derivative Liability, Noncurrent
AVALO THERAPEUTICS, INC. (AVTX) had Derivative Liability, Noncurrent of $18.53 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Other than Long-Term Debt, Noncurrent
us-gaap:DerivativeLiabilitiesNoncurrent · last filed 2026-08-06
- 2026-06-30: Derivative Liability, Noncurrent $18.53M.
- 2026-03-31: Derivative Liability, Noncurrent $17.52M.
- 2025-12-31: Derivative Liability, Noncurrent $18.00M.
- 2025-09-30: Derivative Liability, Noncurrent $23.16M.
| Period end | Derivative Liability, Noncurrent |
|---|---|
| 2026-06-30 | $18.53M 10-Q · filed 2026-08-06 |
| 2026-03-31 | $17.52M 10-Q · filed 2026-05-13 |
| 2025-12-31 | $18.00M 10-Q · filed 2026-08-06 |
| 2025-09-30 | $23.16M 10-Q · filed 2025-11-06 |
| 2025-06-30 | $10.26M 10-Q · filed 2025-08-07 |
| 2025-03-31 | $7.74M 10-Q · filed 2025-05-12 |
| 2024-12-31 | $8.12M 10-K · filed 2026-03-23 |
| 2024-09-30 | $11.81M 10-Q · filed 2024-11-07 |
| 2024-06-30 | $10.71M 10-Q · filed 2024-08-12 |
| 2024-03-31 | $5.67M 10-Q/A · filed 2024-07-11 |
| 2023-12-31 | $5.55M 10-K · filed 2025-03-20 |
| 2023-09-30 | $4.95M 10-Q · filed 2023-11-09 |
| 2023-06-30 | $5.05M 10-Q · filed 2023-08-03 |
| 2023-03-31 | $5.01M 10-Q · filed 2023-05-04 |
| 2022-12-31 | $4.83M 10-K · filed 2024-03-29 |
| 2021-12-31 | $0.00 10-K · filed 2023-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 | |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |